MS-III (Multisystem) Module — Final Year MBBS

AIM LEARNING CYCLE | FINAL YEAR MBBS | KMU CURRICULUM

Concept Integration

Topic 8. Systemic Autoimmune & Connective Tissue Diseases

MS Module | Integrated Clinical Understanding | Rapid Revision

1. THE TOPIC IN ONE CONNECTED FLOW

Systemic autoimmune diseases develop when immune responses damage normal tissues. The type of immune injury determines whether a patient develops inflammation, thrombosis, fibrosis, gland dysfunction or muscle weakness. Recognizing this relationship helps connect clinical presentation with autoimmune investigations, organ assessment and treatment.

1. IMMUNE DYSREGULATION

Loss of self-tolerance → autoantibodies and abnormal immune activation

↓

2. MAIN PATHOLOGICAL MECHANISMS

Immune-complex inflammation (SLE) • Antibody-associated thrombosis (APS) • Vasculopathy and fibrosis (systemic sclerosis) • Glandular or muscle inflammation (Sjögren syndrome and inflammatory myopathies)

↓

3. TISSUE AND ORGAN DYSFUNCTION

Glomerular injury • Vascular occlusion • Skin and lung fibrosis • Reduced tear and saliva production • Skeletal muscle injury

↓

4. CLINICAL PRESENTATION

Rash, arthritis and proteinuria • Thrombosis or pregnancy loss • Raynaud phenomenon and skin tightening • Sicca symptoms • Proximal muscle weakness

↓

5. TARGETED DIAGNOSTIC ASSESSMENT

Clinical pattern + ANA and disease-specific antibodies + CBC, urine, renal function, muscle enzymes or organ-specific tests

↓

6. TARGETED TREATMENT

Immunomodulation or immunosuppression for inflammatory injury • Anticoagulation for thrombotic APS • Organ-specific treatment and supportive care

↓

7. OUTCOME AND LONG-TERM MONITORING

Disease control and organ protection → prevention of renal failure, recurrent thrombosis, pulmonary complications and treatment toxicity

2. KEY CLINICAL CONNECTIONS

Clinical Connection 1 — SLE, Childhood SLE and Renal Disease

Loss of immune tolerance
→
Autoantibodies and immune-complex deposition
→
Complement activation and tissue inflammation

Glomerular injury
→
Proteinuria, hematuria and hypertension
→
Urinalysis, creatinine and urine protein assessment
→
Kidney biopsy when indicated

Biopsy class
→
Class III/IV: proliferative nephritis; Class V: membranous nephritis
→
Severity-based immunosuppression to preserve renal function

Childhood SLE more frequently involves major organs. Growth, renal function and treatment-related complications require long-term monitoring.

Clinical Connection 2 — Antiphospholipid Syndrome and Systemic Sclerosis

Antiphospholipid antibodies
→
Prothrombotic state
→
Venous/arterial thrombosis or pregnancy morbidity
→
Persistent antibody testing and appropriate antithrombotic treatment

Systemic sclerosis vasculopathy and fibrosis
→
Raynaud phenomenon, skin thickening and internal-organ injury
→
Vascular, pulmonary and renal assessment
→
Organ-directed treatment

APS primarily causes thrombotic injury, while systemic sclerosis causes vascular dysfunction and fibrosis. New severe hypertension with acute kidney injury in systemic sclerosis suggests renal crisis and requires urgent ACE-inhibitor treatment.

Clinical Connection 3 — Sjögren Syndrome, Inflammatory Myopathies and Treatment

Autoimmune exocrine-gland inflammation
→
Reduced tears and saliva
→
Dry eyes, dry mouth and dental injury
→
Tear/saliva replacement and organ assessment

Immune-mediated skeletal muscle injury
→
Symmetrical proximal weakness ± dermatomyositis rash
→
CK, MRI/EMG and selected biopsy
→
Immunosuppression and rehabilitation

Immunosuppressive treatment
→
Reduced immune injury
→
Better disease control
→
CBC, organ-function and infection monitoring

3. AIM HIGH-YIELD INTEGRATION REVIEW

⭐ 1. Clinical findings + autoantibodies → diagnosis

ANA supports screening, but disease-specific antibodies and organ findings provide greater diagnostic meaning. A positive ANA alone does not establish SLE.

2. Immune-complex injury → lupus nephritis

Proteinuria and hematuria suggest renal involvement; biopsy differentiates mesangial, proliferative, membranous and sclerosing lesions. Renal dysfunction in RA may instead reflect amyloidosis, associated glomerular disease or drug toxicity.

⭐ 3. APS antibodies → thrombosis and pregnancy complications

Persistent antiphospholipid antibodies support APS in the appropriate clinical setting. Thrombotic APS requires anticoagulation; obstetric APS commonly requires aspirin and heparin.

4. Vasculopathy and fibrosis → systemic sclerosis

Raynaud phenomenon and sclerodactyly suggest systemic sclerosis; lung and renal assessment identify major organ complications, while sudden hypertension with acute kidney injury signals possible renal crisis.

5. Exocrine-gland inflammation → Sjögren syndrome

Sicca symptoms are supported by anti-Ro/SSA, objective tear testing or salivary gland assessment. Persistent gland enlargement raises concern for lymphoma; tubulointerstitial injury may cause distal renal tubular acidosis.

⭐ 6. Muscle inflammation → proximal weakness

Elevated CK supports muscle injury; heliotrope rash and Gottron papules suggest dermatomyositis. Dysphagia, lung involvement and malignancy-associated risk influence assessment.

7. Childhood SLE → higher concern for organ damage

Renal and hematological involvement can be prominent in children. Early recognition and treatment must be balanced with monitoring of growth, development and medication toxicity.

⭐ 8. Drug mechanism → disease control and monitoring

Hydroxychloroquine provides background immunomodulation; glucocorticoids suppress inflammation; methotrexate, azathioprine and mycophenolate provide steroid-sparing immunosuppression. Monitor retinal, hematological, hepatic, renal and infection-related risks as appropriate.

AIM Exam Trap — Lupus anticoagulant

Lupus anticoagulant may prolong aPTT in laboratory testing, but in the patient it is associated with an increased risk of thrombosis, not a typical bleeding tendency.